Metabolites (Jan 2022)

Ubiquitous Aberration in Cholesterol Metabolism across Pancreatic Ductal Adenocarcinoma

  • Venugopal Gunda,
  • Thiago C. Genaro-Mattos,
  • Jyoti B. Kaushal,
  • Ramakanth Chirravuri-Venkata,
  • Gopalakrishnan Natarajan,
  • Kavita Mallya,
  • Paul M. Grandgenett,
  • Karoly Mirnics,
  • Surinder K. Batra,
  • Zeljka Korade,
  • Satyanarayana Rachagani

DOI
https://doi.org/10.3390/metabo12010047
Journal volume & issue
Vol. 12, no. 1
p. 47

Abstract

Read online

Pancreatic cancer (PC) is characterized by metabolic deregulations that often manifest as deviations in metabolite levels and aberrations in their corresponding metabolic genes across the clinical specimens and preclinical PC models. Cholesterol is one of the critical metabolites supporting PC, synthesized or acquired by PC cells. Nevertheless, the significance of the de novo cholesterol synthesis pathway has been controversial in PC, indicating the need to reassess this pathway in PC. We utilized preclinical models and clinical specimens of PC patients and cell lines and utilized mass spectrometry-based sterol analysis. Further, we also performed in silico analysis to corroborate the significance of de novo cholesterol synthesis pathway in PC. Our results demonstrated alteration in free sterol levels, including free cholesterol, across in vitro, in vivo, and clinical specimens of PC. Especially, our sterol analyses established consistent alterations in free cholesterol across the different PC models. Overall, this study demonstrates the significance and consistency in deviation of cholesterol synthesis pathway in PC while showing the aberrations in sterol metabolite intermediates and the related genes using preclinical models, in silico platforms, and the clinical specimens.

Keywords